Safety Monitoring Recommendations Based on the available clinical trial data, clinicians prescribing orforglipron should: (1) counsel patients about expected GI side effects during dose escalation, (2) follow the recommended dose-titration schedule to minimize GI intolerance, (3) monitor for signs of pancreatitis and discontinue if suspected, (4) assess hepatic and renal function at baseline and periodically, (5) screen for personal or family history of MTC or MEN 2, and (6) review concomitant medications for potential CYP3A-mediated drug interactions
NSAIDs, having the ability to inhibit the synthesis of gastroprotective prostaglandins, exhibit gastrototoxic action
It should also be noted that 8 days of water-only fasting also resulted in a decrease in the volume of excreted urine and an increase in its specific gravity
This impact will continue as adoption ramps up to a peak over the next few years
AOD-9604 liberates fat from adipocytes, but liberated fat sitting in plasma does nothing except potentially raise LDL-C if it's not oxidised
